Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer.
Von Pawel, J Jotte, R Spigel, D O'Brien, M Socinski, M Mezger, J Steins, M Bosquée, L Bubis, J Nackaerts, K
Von Pawel, J
Jotte, R
Spigel, D
O'Brien, M
Socinski, M
Mezger, J
Steins, M
Bosquée, L
Bubis, J
Nackaerts, K
Citations
Altmetric:
Abstract
Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in small-cell lung cancer (SCLC) in phase II trials. This phase III trial compared the safety and efficacy of amrubicin versus topotecan as second-line treatment for SCLC.
Affiliation
Description
Date
2014-11-10
Publisher
Collections
Keywords
Type
Article
Citation
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer. 2014: J Clin Oncol